1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24526
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNakou, E. S.en
dc.contributor.authorFilippatos, T. D.en
dc.contributor.authorAgouridis, A. P.en
dc.contributor.authorKostara, C.en
dc.contributor.authorBairaktari, E. T.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T19:41:45Z-
dc.date.available2015-11-24T19:41:45Z-
dc.identifier.issn1558-9307-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24526-
dc.rightsDefault Licence-
dc.subjectAnti-Obesity Agents/*pharmacologyen
dc.subjectAnticholesteremic Agents/pharmacologyen
dc.subjectApolipoprotein C-II/metabolismen
dc.subjectApolipoprotein C-III/metabolismen
dc.subjectAzetidines/*pharmacologyen
dc.subjectDiet, Fat-Restricteden
dc.subjectDrug Therapy, Combinationen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLactones/*pharmacologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectObesity/diet therapy/*drug therapyen
dc.subjectTriglycerides/*metabolismen
dc.titleThe effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patientsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1007/s11745-010-3409-0-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20379853-
heal.identifier.secondaryhttp://www.springerlink.com/content/24k51128823674n1/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2010-
heal.abstractWe investigated the factors influencing triglycerides (TG) reduction during ezetimibe, alone or combined with orlistat, administration. Eighty-six obese hypercholesterolemic subjects were prescribed a low-fat diet and were randomized to ezetimibe (E group), orlistat (O group), or both (OE group) for 6 months. Plasma TG and apolipoprotein (apo) C-III reduction was significantly greater in the combination group compared with monotherapy. Multivariate analysis showed that in E group apoC-III reduction and baseline TG levels were independently positively correlated, whereas baseline apoC-II levels were negatively correlated, with TG lowering. In OE group apoC-III reduction was the only independent contributor to TG reduction.en
heal.journalNameLipidsen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Nakou-2010-The effects of ezeti.pdf189.28 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons